RJK-RT2831 dose-escalation phase Ia
RJK-RT2831-101
Phase 1 small_molecule active
Quick answer
RJK-RT2831 dose-escalation phase Ia for Hematologic Malignancies is a Phase 1 program (small_molecule) at Nanjing Zenshine Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Nanjing Zenshine Pharmaceuticals
- Indication
- Hematologic Malignancies
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active